Methods for treating cancer using 6,8-bis (benzylthio) octanonic acid
Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.
1. A method of treating a cancer selected from the group consisting of a carcinoma, sarcoma, myeloma, lymphoma, leukemia, a mixed type thereof, and a cancer of the pancreas in a human patient in need thereof, comprising the step of intravenously administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of 6,8-bis(benzylthio)octanoic acid or an ion pair thereof, and a pharmaceutically acceptablediluent for solubilizing 6,8-bis(benzylthio)octanoic acid or an ion pair thereof.
2. The method of claim 1 , wherein the cancer is a cancer of the pancreas.
3. The method of claim 1 , wherein the cancer is a lymphoma.
4. The method of claim 1 , wherein the cancer is a leukemia.
5. The method of claim 1 , wherein the cancer is a carcinoma.
6. The method of claim 1 , wherein the cancer is a sarcoma.
7. The method of claim 1 , wherein the cancer is a myeloma.
8. The method of claim 1 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 20 mg/m 2 to 2500 mg/m 2 .
9. The method of claim 1 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 0.25 mg/m 2 to 3 g/m 2 .
10. The method of claim 2 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 20 mg/m 2 to 500 mg/m 2 .
11. The method of claim 2 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 500 mg/m 2 to 700 mg/m 2 .
12. The method of claim 2 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 500 mg/m 2 .
13. The method of claim 3 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 20 mg/m 2 to 2500 mg/m 2 .
14. The method of claim 3 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 0.25 mg/m 2 to 3 g/m 2 .
15. The method of claim 3 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 2500 mg/m 2 .
16. The method of claim 4 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 20 mg/m 2 to 2500 mg/m 2 .
17. The method of claim 4 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 0.25 mg/m 2 to 3 g/m 2 .
18. A method of treating carcinoma, sarcoma, myeloma, lymphoma, leukemia, or a mixed type thereof, or a cancer of the pancreas in a human patient in need thereof, comprising the step of intravenously administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of 6,8-bis(benzylthio)octanoic acid or an ion pair thereof, and a pharmaceutically acceptable aqueous diluent for solubilizing 6,8-bis(benzylthio)octanoic acid or an ion pair thereof.
19. The method of claim 18 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered for the treatment of a cancer of the pancreas.
20. The method of claim 18 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered for the treatment of lymphoma.
21. The method of claim 18 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered for the treatment of leukemia.
22. The method of claim 18 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered for the treatment of carcinoma.
23. The method of claim 18 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered for the treatment of sarcoma.
24. The method of claim 18 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered for the treatment of myeloma.
25. The method of claim 18 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 20 mg/m 2 to 2500 mg/m 2 .
26. The method of claim 18 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 0.25 mg/m 2 to 3 g/m 2 .
27. The method of claim 19 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 20 mg/m 2 to 500 mg/m 2 .
28. The method of claim 19 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 500 mg/m 2 to 700 mg/m 2 .
29. The method of claim 19 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 500 mg/m 2 .
30. The method of claim 20 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 20 mg/m 2 to 2500 mg/m 2 .
31. The method of claim 20 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 0.25 mg/m 2 to 3 g/m 2 .
32. The method of claim 20 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 2500 mg/m 2 .
33. The method of claim 21 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 20 mg/m 2 to 2500 mg/m 2 .
34. The method of claim 21 , wherein the 6,8-bis(benzylthio)octanoic acid or an ion pair thereof is administered at a dose of 0.25 mg/m 2 to 3 g/m 2 .
35. The method of claim 25 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
36. The method of claim 26 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
37. The method of claim 27 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
38. The method of claim 28 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
39. The method of claim 29 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
40. The method of claim 30 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
41. The method of claim 31 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
42. The method of claim 32 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
43. The method of claim 33 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.
44. The method of claim 34 , wherein the pharmaceutically acceptable aqueous diluent is a dextrose solution which contains an amount of dextrose ranging from 2.5% to 10% by weight.